STD screening advancements may lead to earlier detection, faster results

New developments in testing for sexually transmitted diseases (STDs) achieved by Abbott Diagnostics, a medical supplies company, were recently presented at this year's American Association for Clinical Chemistry (AACC) Lab Expo. Healthcare officials report that these findings may help improve early detection of several infections, including HIV, gonorrhea and chlamydia.

During recent studies, Abbott researchers used a molecular assay, a procedure that measures cell activity levels, in order to identify the cells of two different types of STDs. The team was also able to develop equipment that can analyze test results quicker and more efficiently.

The capability to diagnose these infections sooner through the use of assays and enhanced screening materials may help patients begin their treatment plans more quickly. Also, earlier detection will help people share their diagnosis with their partners in a timely manner, resulting in possibly slowing the spread of these diseases.

Brian Blaser, senior vice president of diagnostics at Abbott, stated that the company's presentation will feature "our latest assays and systems which offer solutions to meet the demanding needs of healthcare institutions by improving operational efficiency, clinical outcomes, and physician, patient and laboratory satisfaction."